Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: J Immunol. 2014 Nov 26;194(1):142–150. doi: 10.4049/jimmunol.1401777

Figure 5. PAR-1 and PAR-2 affect fibrocyte differentiation.

Figure 5

PBMC were incubated with (A–C) inhibitors of protease activated receptor-2 (PAR-2) or (D–F) inhibitors of protease activated receptor-1 (PAR-1) before mixing with (A, D) trypsin, (B, E) tryptase, or (C, F) thrombin at the indicated concentrations. (G) PAR-1 agonists or (H) PAR-2 agonists were added to PBMC at the indicated concentrations. After 5 days, fibrocytes were counted as in Figure 1. Values are mean ± SEM, n=6. * indicates p < .05, ** p < .01, and *** p < .001 compared to the agonist-free or protease-free control (t-test) for ENMD-1068, SCH 79797, SFLLRN-NH2, and 2f–LIGRL-NH2. x indicates p < .05 for FSLLRY-NH2, Vorapaxar, SFLLRNDKYEPF, and AC 55541, each n=3. In G and H, arrows indicate the published EC50 concentrations.